WOWenwei Ouyang

Wenwei Ouyang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenwei Ouyang has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Zehuai Wen

    Guangdong Provincial Hospital of Chinese Medicine (Second Affiliated Hospital of Guangzhou University of Chinese Medicine) Guangdong Provincial Academy of Chinese Medical Sciences Guangzhou China

    4 shared publications
  • Fang Tang

    Department of Chronic Disease Management, The Second Clinical College, Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, Guangdong, China

    2 shared publications
  • Li Zhou

    Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China

    2 shared publications
  • Meiling Xuan

    Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China; State Key Laboratory of Dampness Syndrome of Chinese Medicine, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

    2 shared publications
  • Xiankun Chen

    Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China

    2 shared publications
  • Xiaohui Guo

    Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China

    2 shared publications

Latest Publications

  • Open Access

    Self‐Management Improves Long‐Term CKD Prognosis: A 10‐Year Retrospective Cohort Study From China

    by Hui-Fen Chen, Xing-Le Liang, Yan Han, Yu-Han Shen, Xian-Long Zhang, Fang Tang, Li-Zhe Fu, Yue-Yu Gu, Tao Zou, Xin-Dong Qin, et al.

    Background: Self‐management (SMP) is a novel treatment comprised of multidimensional interventions. Researchers have reported its reliable effects on short‐term improvements in surrogate indicators like 24‐h urinary protein excretion and systolic blood pressure. However, whether it has any effect on long‐term changes in other surrogate indicators and chronic kidney disease (CKD) endpoints remains unclear. Methods: Patients with CKD stages 3‐4 were grouped into either a SMP group or a nonself‐management (non‐SMP) group whether they had complied any of five characterized elements: regular visits, medication adjustment, nutritional intervention, lifestyle modification, education, and behavior guide. We used 1:1 nearest‐neighbor propensity score matching (PSM) to balance between‐group differences. Cox regression was used to explore the long‐term association between SMP and composite outcomes (all‐cause mortality, end‐stage kidney disease (ESKD), ≥ 50% decline in estimated glomerular filtration rate (eGFR), or doubling of serum creatinine (SCr) from baseline). Linear mixed‐effects (LME) model and marginal means comparisons were used to surrogate indicators analysis. Results: The study included 1160 patients with a median follow‐up of 27.20 months. Among them, 580 individuals were in the SMP group and 580 were in the non‐SMP group. In the non‐SMP group, the median follow‐up was 24.48 (12.21, 43.39) months with 174 (30.00%) events, whereas the SMP group had a median follow‐up of 29.34 (14.75, 42.00) months with 134 (23.10%) composite outcomes. Participation in a SMP program was associated with a 30.9% reduction in CKD progression risk (hazard ratio (HR) of composite outcome: 0.691, 95% CI: 0.549–0.869, and p = 0.002). LME and marginal means comparison indicated that patients with SMP had higher mean difference of eGFR and serum albumin (Alb) than the non‐SMP individuals (mean difference of eGFR: 1.791 (0.721, 2.861) mL/min/1.73 m 2 , p = 0.001; marginal mean difference of eGFR: 2.560 (1.660, 3.470) mL/min/1.73 m 2 , p < 0.0001; mean difference of Alb: 0.654 (0.202, 1.105) g/L, p = 0.005; and marginal mean difference of Alb: 0.460 (0.166, 0.753) g/L, p = 0.002). Conclusion: SMP programs are associated with a 30.9% reduction in CKD progression risk and improvements in kidney function and nutrition‐related surrogate markers, benefiting CKD patients in stages 3‐4.

  • Huoxiang Zhengqi oral liquid for irritable bowel syndrome with diarrhea: a multicenter, double-blind, randomized controlled trial

    by Xiaohui Guo, Ting Cheng, Meiling Xuan, Geng Li, Li Zhou, Wenwei Ouyang, Xiankun Chen, Xiaojun Yang, Jiehong Wang, Biao Gong, et al.


  • Effect of Xuefu zhuyu oral liquid on tension-type headache: A randomized clinical trial

    by Li Zhou, Jun Tan, Geng Li, Xiankun Chen, Meiling Xuan, Xiaohui Guo, Li Bai, Rong Hua, Jing Chen, Jie Zhang, et al.


  • Study on Damage of Myocardial Tissue Under Low-Dose Heart Irradiation in Rats

    by Z. Feng, B. Lu, W. Ouyang, S.F. Su, Y. Wan, Z. Ma, Q. Li, Y. Geng, D. Cao, S. Fu

  • Open Access

    Chinese Herbal Formula Huoxiang Zhengqi for Dampness Pattern in Atopic Dermatitis and Diarrhea-Predominant Irritable Bowel Syndrome: Rationale and Design of a Master Protocol

    by Qian Huang, Xiaohui Guo, Meiling Xuan, Wenwei Ouyang, Zehuai Wen

    Introduction. Atopic dermatitis (AD) and diarrhea-predominant irritable bowel syndrome (IBS-D) are two recurrent diseases with limited effective treatments. In Chinese Medicine (CM) theory, they may share dampness pattern as the same dominant pathogenesis at a certain stage and, thus, can be treated with the same method. While Chinese herbal formula Huoxiang Zhengqi (HXZQ) has been reported as an effective dampness-resolving therapy for both AD and IBS-D, further high-quality clinical studies are still needed. In addition, HXZQ lacks accurate clinical positioning based on CM patterns. Therefore, we utilize a master protocol design to evaluate HXZQ for dampness pattern simultaneously in AD and IBS-D, with the aim of identifying the pattern-defined population of HXZQ. Methods and Analysis. This master protocol design includes two randomized controlled trials (RCTs) and a real-world observational study. Based on two registry cohorts of AD and IBS-D, patients with dampness pattern will be enrolled in the RCTs to receive either HXZQ oral liquid or a placebo for 4 weeks and then will be followed up for another 4 weeks, while patients with nondampness pattern will constitute the observational study and experience a 12-week follow-up. A total of 678 AD patients and 322 IBS-D patients will be recruited from 14 hospitals in China over a 3-year period. The eczema area and severity index (EASI) and the proportion of responders for adequate relief (AR) are the primary outcomes in AD and IBS-D, respectively. Analysis will be undertaken separately in each substudy, and then an overall analysis combining multiple subgroups will be performed to comprehensively investigate the effect of HXZQ. Discussion. This study will provide high-quality efficacy evidence of HXZQ for AD and IBS-D patients and give an example of postmarketing evaluation for CM products under the pattern dominating different disease research model. The study is registered with ChiCTR1900026700 and ChiCTR1900026837.


  • Topical therapy with rhubarb navel plasters in patients with chronic constipation: Results from a prospective randomized multicenter study

    by Lin Wei, Yueming Luo, Xiaopei Zhang, Yangchen Liu, Martin Gasser, Fang Tang, Wen-Wei Ouyang, Hengqiu Wei, Shengzhen Lu, Zhen Yang, et al.


  • Open Access

    Efficacy and indication optimization of Chinese medicine (Tiao-Chang Ke-Min granules) for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized controlled trial

    by Qian Li, Bei-Ping Zhang, Shao-Gang Huang, Wen-Wei Ouyang, Jian-Hui Xie, Ze-Huai Wen, Xiao-Bo Yang

    Background: Irritable bowel syndrome (IBS) is a chronic, recurring condition, prevalent in the general population. Current medication treatments usually leave patients undertreated. Nowadays, Chinese medicine (CM) is being considered as a promising treatment approach for IBS. However, due to methodological limitations, there is no strong evidence to support CM. Although IBS relapses are common, the relapse assessment has always been neglected in CM study designs. Meanwhile, in clinical practice and studies, it has been found that certain CM formulas can only benefit certain kinds of patients. Discovering what population and illness characteristics likely respond to outcomes may help improve the effectiveness of CM. The aims of this study are to evaluate the efficacy and safety of Tiao-Chang Ke-Min (TCKM) granules for IBS, especially in reducing IBS symptoms' relapse, by a highquality randomized controlled trial and then to optimize the indication of the TCKM granules. Methods/design: This is a parallel-group, randomized, double-blind, placebo-controlled trial embedded with outcome predictive factors. Eligible patients with diarrhea-predominant IBS will be randomized into either a TCKM granule group or a placebo group. Patients from both groups will receive health education. The treatment duration is 4 weeks and the follow-up is 12 weeks. The primary outcome is global improvement measured with adequate relief (AR). The second outcome measures include time until relief, time until first relapse, total relapse times, long-term effectiveness, individual symptoms, IBS-Symptom Severity Score (IBS-SSS), IBS-Quality of Life Questionnaire (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS). Predictive factors associated with patient and illness characteristics have been widely collected. These factors will be embedded in this trial for further identification. Discussion: This trial may provide high-quality evidence on the efficacy and safety of TCKM granules for IBS and a more accurate indication. Importantly, this trial will provide a new research method for improving the therapeutic effects of CM for clinicians and researchers. To address IBS relapse assessment, a series of special definitions of relapse incidents has been made for this trial.